Get the Stockscreener App
1.44
4.00%
-0.06
After Hours:
1.46
0.02
+1.39%
Zentalis Pharmaceuticals Inc stock is traded at $1.44, with a volume of 624.92K.
It is down -4.00% in the last 24 hours and down -10.56% over the past month.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
See More
Previous Close:
$1.50
Open:
$1.49
24h Volume:
624.92K
Relative Volume:
0.85
Market Cap:
$103.88M
Revenue:
-
Net Income/Loss:
$-292.19M
P/E Ratio:
-0.3172
EPS:
-4.54
Net Cash Flow:
$-208.41M
1W Performance:
-16.28%
1M Performance:
-10.56%
6M Performance:
-0.69%
1Y Performance:
-56.63%
1-Day Range:
$1.43
$1.54
1-Week Range:
$1.43
$1.77
52-Week Range:
$1.01
$4.44
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
(858) 263-4333
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
1.44 | 108.20M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-24 | Upgrade | Wedbush | Underperform → Neutral |
| Jun-20-24 | Downgrade | UBS | Buy → Neutral |
| Jun-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-18-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-18-24 | Downgrade | Wedbush | Neutral → Underperform |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-08-23 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-07-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-12-22 | Initiated | Cowen | Outperform |
| Apr-06-22 | Initiated | Wells Fargo | Overweight |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-29-21 | Initiated | Oppenheimer | Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Jan-20-21 | Initiated | Wedbush | Outperform |
| Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Guggenheim | Buy |
| Apr-28-20 | Initiated | Jefferies | Buy |
| Apr-28-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
Relative strength of Zentalis Pharmaceuticals Inc. in sector analysisJuly 2025 Trends & AI Based Buy/Sell Signal Reports - newser.com
Is Zentalis Pharmaceuticals Inc. forming a bottoming baseQuarterly Earnings Summary & High Yield Equity Trading Tips - newser.com
Is Zentalis Pharmaceuticals Inc. stock in correction or buying zoneWeekly Risk Report & AI Powered Trade Plan Recommendations - newser.com
What indicators show strength in Zentalis Pharmaceuticals Inc.2025 Risk Factors & High Win Rate Trade Alerts - newser.com
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zentalis (Nasdaq: ZNTL) awards 17,000 inducement options to new employee - Stock Titan
Why analysts upgrade Zentalis Pharmaceuticals Inc. stockJuly 2025 Fed Impact & Low Drawdown Investment Ideas - newser.com
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Zentalis (NASDAQ: ZNTL) to participate in Guggenheim and Stifel healthcare conferences - Stock Titan
Why Zentalis Pharmaceuticals Inc. stock is in analyst buy zoneWeekly Risk Summary & Daily Oversold Bounce Ideas - newser.com
Can Zentalis Pharmaceuticals Inc. stock beat market expectations this quarterEarnings Recap Report & Low Risk Entry Point Tips - newser.com
Will Zentalis Pharmaceuticals Inc. stock keep outperforming rivals2025 Earnings Impact & AI Enhanced Trading Signals - newser.com
How currency fluctuations impact Zentalis Pharmaceuticals Inc. stockEarnings Growth Report & Smart Investment Allocation Tips - newser.com
Can Zentalis Pharmaceuticals Inc. rally from current levelsInflation Watch & Real-Time Chart Pattern Alerts - newser.com
Why Zentalis Pharmaceuticals Inc. stock remains undervaluedPortfolio Risk Report & AI Driven Price Predictions - newser.com
Can Zentalis Pharmaceuticals Inc. stock reach $100 price targetEarnings Miss & Community Driven Trade Alerts - newser.com
How Zentalis Pharmaceuticals Inc. stock benefits from strong dollarInsider Buying & Daily Entry Point Trade Alerts - newser.com
How Future Regulation Could Impact Future Lifestyle Fashions Limited ProfitabilitySector Leadership Analysis & Breakout Portfolio Performance - earlytimes.in
Multi asset correlation models including Zentalis Pharmaceuticals Inc.2025 Top Gainers & Daily Chart Pattern Signal Reports - newser.com
What recovery options are there for Zentalis Pharmaceuticals Inc.Profit Target & AI Forecast for Swing Trade Picks - newser.com
Zentalis Pharmaceuticals Stock Faces Pressure as Insider Bets Turn Negative - AD HOC NEWS
Zentalis Pharmaceuticals Slides As Insider Purchases Lose Another US$37k - simplywall.st
How to build a custom watchlist for Zentalis Pharmaceuticals Inc.2025 Price Targets & Verified Chart Pattern Trade Signals - newser.com
How Zentalis Pharmaceuticals Inc. stock performs in high volatility marketsStop Loss & Fast Gaining Stock Strategy Reports - newser.com
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):